ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2019
High neurofilament levels are associated with clinically definite multiple sclerosis in children and adults with clinically isolated syndrome.
Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Neurofilament Biomarkers in Neurology: From Neuroinflammation to Neurodegeneration, Bridging Established and Novel Analytical Advances with Clinical Practice.International journal of molecular sciences · 2025Review
- No Relation Between Cognitive Impairment, Physical Disability and Serum Biomarkers in a Cohort of Progressive Multiple Sclerosis Patients.Biomolecules · 2025Article
- Steps toward the implementation of neurofilaments in multiple sclerosis: patient profiles to be prioritized in clinical practice.Frontiers in neurology · 2025Article
- Determination of systemic inflammatory biomarkers in multiple sclerosis.Journal of medical biochemistry · 2024Article
- Association of intestinal dysbiosis with susceptibility to multiple sclerosis: Evidence from different population studies (Review).Biomedical reports · 2023Review
- Protein biomarkers in multiple sclerosis.Encephalitis (Seoul, Korea) · 2023Review
- The 2022 Lady Estelle Wolfson lectureship on neurofilaments.Journal of neurochemistry · 2022Review
- Serum neurofilament light in MS: The first true blood-based biomarker?Multiple sclerosis (Houndmills, Basingstoke, England) · 2022Review
- Evolution of clinically isolated syndrome to pediatric-onset multiple sclerosis and a review of the literature.Turkish journal of medical sciences · 2022Review
- Serum-Based Biomarkers in Neurodegeneration and Multiple Sclerosis.Biomedicines · 2022Review
- Neurofilament light chain and glial fibrillary acidic protein levels in metachromatic leukodystrophy.Brain : a journal of neurology · 2022Article
- Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations.International journal of molecular sciences · 2022Review
- The potential of serum neurofilament as biomarker for multiple sclerosis.Brain : a journal of neurology · 2021Review
- Cerebrospinal fluid markers in incident pediatric-onset multiple sclerosis: a nationwide study.Scientific reports · 2021Article
- The Evolution of Neurofilament Light Chain in Multiple Sclerosis.Frontiers in neuroscience · 2021Review
- Neurofilament Proteins as Biomarkers to Monitor Neurological Diseases and the Efficacy of Therapies.Frontiers in neuroscience · 2021Review
- Neurofilament light chain as a biomarker for diagnosis of multiple sclerosis.EXCLI journal · 2021Review
- Circulating Neurofilament Light Chain Is Associated With Survival After Pediatric Cardiac Arrest.Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies · 2020Article
- Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2020Article
- Serum Neurofilament Levels in Children With Febrile Seizures and in Controls.Frontiers in neuroscience · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA promising biomarker for axonal damage early in the disease course of multiple sclerosis (MS) is neurofilament light chain (NfL). It is unknown whether NfL has the same predictive value for MS diagnosis in children as in adults.
objectiveTo explore the predictive value of NfL levels in cerebrospinal fluid (CSF) for MS diagnosis in paediatric and adult clinically isolated syndrome (CIS) patients.
methodsA total of 88 adult and 65 paediatric patients with a first attack of demyelination were included and followed (mean follow up-time in adults: 62.8 months (standard deviation (SD) ±38.7 months) and 43.8 months (SD ±27.1 months) in children). Thirty control patients were also included. Lumbar puncture was done within 6 months after onset of symptoms. NfL was determined in CSF using enzyme-linked immunosorbent assay (ELISA). COX regression analyses were used to calculate hazard ratios (HR) for clinically definite multiple sclerosis (CDMS) diagnosis.
resultsAfter adjustments for age, oligoclonal bands (OCB), and asymptomatic T2 lesions on baseline magnetic resonance imaging (MRI), increased NfL levels in both paediatric and adult CIS patients were associated with a shorter time to CDMS diagnosis (children HR = 3.7; p = 0.007, adults HR = 2.1; p = 0.032). For CIS patients with a future CDMS diagnosis, children showed higher NfL levels than adults (geometric mean 4888 vs 2156 pg/mL; p = 0.007).
conclusionCSF NfL levels are associated with CDMS diagnosis in children and adults with CIS. This makes NfL a promising predictive marker for disease course with potential value in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.